- Home
- LILA vs DVAX Comparison
LILA vs DVAX Comparison
Compare LILA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- DVAX
- Stock Information
- Founded
- LILA 2017
- DVAX 1996
- Country
- LILA Bermuda
- DVAX United States
- Employees
- LILA N/A
- DVAX N/A
- Industry
- LILA Cable & Other Pay Television Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- LILA Telecommunications
- DVAX Health Care
- Exchange
- LILA Nasdaq
- DVAX Nasdaq
- Market Cap
- LILA 1.3B
- DVAX 1.3B
- IPO Year
- LILA N/A
- DVAX 2004
- Fundamental
- Price
- LILA $7.75
- DVAX $9.67
- Analyst Decision
- LILA Sell
- DVAX Buy
- Analyst Count
- LILA 1
- DVAX 4
- Target Price
- LILA $6.50
- DVAX $26.50
- AVG Volume (30 Days)
- LILA 452.8K
- DVAX 1.9M
- Earning Date
- LILA 11-05-2025
- DVAX 11-06-2025
- Dividend Yield
- LILA N/A
- DVAX N/A
- EPS Growth
- LILA N/A
- DVAX N/A
- EPS
- LILA N/A
- DVAX N/A
- Revenue
- LILA $4,409,700,000.00
- DVAX $316,268,000.00
- Revenue This Year
- LILA $1.21
- DVAX $23.23
- Revenue Next Year
- LILA $2.90
- DVAX $16.57
- P/E Ratio
- LILA N/A
- DVAX N/A
- Revenue Growth
- LILA N/A
- DVAX 26.66
- 52 Week Low
- LILA $4.26
- DVAX $9.21
- 52 Week High
- LILA $10.79
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- LILA 54.34
- DVAX 50.44
- Support Level
- LILA $7.46
- DVAX N/A
- Resistance Level
- LILA $8.14
- DVAX $9.94
- Average True Range (ATR)
- LILA 0.23
- DVAX 0.28
- MACD
- LILA -0.08
- DVAX -0.39
- Stochastic Oscillator
- LILA 45.39
- DVAX 92.66
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.